$RVNC
Revance Therapeutics, Inc.

2020 Q4 Form 10-Q Financial Statement

#000147929020000105 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $11.13M $3.835M $46.00K
YoY Change 12405.62% 8236.96% -98.05%
Cost Of Revenue $3.660M $1.090M
YoY Change
Gross Profit $7.470M $2.750M
YoY Change
Gross Profit Margin 67.12% 71.71%
Selling, General & Admin $51.88M $48.18M $16.74M
YoY Change 176.4% 187.85% 18.26%
% of Gross Profit 694.51% 1752.11%
Research & Development $29.24M $29.13M $25.85M
YoY Change 6.37% 12.7% 18.3%
% of Gross Profit 391.43% 1059.27%
Depreciation & Amortization $4.320M $3.780M $730.0K
YoY Change 468.42% 417.81% 65.91%
% of Gross Profit 57.83% 137.45%
Operating Expenses $85.44M $77.31M $42.59M
YoY Change 84.7% 81.55% 18.28%
Operating Profit -$77.97M -$77.13M -$42.54M
YoY Change 68.88% 81.31% 26.45%
Interest Expense -$2.870M $4.334M $0.00
YoY Change -392.86%
% of Operating Profit
Other Income/Expense, Net -$190.0K -$146.0K -$130.0K
YoY Change 46.15% 12.31% -9.72%
Pretax Income -$81.03M -$81.26M -$41.41M
YoY Change 78.76% 96.23% 26.13%
Income Tax -$2.720M $0.00 $0.00
% Of Pretax Income
Net Earnings -$78.31M -$81.26M -$41.41M
YoY Change 72.77% 96.23% 26.12%
Net Earnings / Revenue -703.59% -2118.83% -90019.57%
Basic Earnings Per Share -$1.34
Diluted Earnings Per Share -$1.236M -$1.34 -$956.1K
COMMON SHARES
Basic Shares Outstanding 66.55M shares 60.53M shares 44.10M shares
Diluted Shares Outstanding 60.53M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $436.5M $435.8M $209.0M
YoY Change 50.47% 108.52% 0.29%
Cash & Equivalents $333.6M $339.4M $58.92M
Short-Term Investments $102.9M $96.40M $150.1M
Other Short-Term Assets $5.800M $7.700M $6.500M
YoY Change -10.77% 18.46% -13.33%
Inventory $5.900M $4.000M
Prepaid Expenses
Receivables $1.829M $2.585M $5.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $450.0M $450.1M $220.6M
YoY Change 51.72% 104.07% 2.17%
LONG-TERM ASSETS
Property, Plant & Equipment $17.50M $14.84M $14.92M
YoY Change 18.6% -0.5% 10.55%
Goodwill $147.0M $144.5M
YoY Change
Intangibles $71.34M $74.85M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.334M $1.154M $2.519M
YoY Change -20.07% -54.19% -14.44%
Total Long-Term Assets $270.2M $262.0M $45.24M
YoY Change 518.56% 479.18% 163.55%
TOTAL ASSETS
Total Short-Term Assets $450.0M $450.1M $220.6M
Total Long-Term Assets $270.2M $262.0M $45.24M
Total Assets $720.2M $712.1M $265.8M
YoY Change 111.65% 167.91% 14.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.66M $7.860M $6.902M
YoY Change 58.01% 13.88% -5.98%
Accrued Expenses $32.94M $37.66M $18.69M
YoY Change 76.74% 101.45% 18.93%
Deferred Revenue $7.851M $10.93M $5.241M
YoY Change -0.76% 108.57% -40.1%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $60.96M $63.65M $34.15M
YoY Change 48.77% 86.37% 7.38%
LONG-TERM LIABILITIES
Long-Term Debt $180.5M $177.4M $0.00
YoY Change
Other Long-Term Liabilities $0.00 $98.30M $80.40M
YoY Change -100.0% 22.26% 320.94%
Total Long-Term Liabilities $0.00 $275.7M $80.40M
YoY Change -100.0% 242.91% 320.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $60.96M $63.65M $34.15M
Total Long-Term Liabilities $0.00 $275.7M $80.40M
Total Liabilities $345.9M $339.3M $114.5M
YoY Change 201.34% 196.25% 124.78%
SHAREHOLDERS EQUITY
Retained Earnings -$1.126B -$1.050B -$798.9M
YoY Change 33.41% 31.43% 24.02%
Common Stock $1.501B $1.421B $950.1M
YoY Change 40.28% 49.54% 14.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $374.3M $372.9M $151.3M
YoY Change
Total Liabilities & Shareholders Equity $720.2M $712.1M $265.8M
YoY Change 111.65% 167.91% 14.06%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$78.31M -$81.26M -$41.41M
YoY Change 72.77% 96.23% 26.12%
Depreciation, Depletion And Amortization $4.320M $3.780M $730.0K
YoY Change 468.42% 417.81% 65.91%
Cash From Operating Activities -$62.31M -$55.69M -$31.95M
YoY Change 85.94% 74.3% 25.74%
INVESTING ACTIVITIES
Capital Expenditures -$2.210M -$780.0K -$1.480M
YoY Change 662.07% -47.3% -51.16%
Acquisitions
YoY Change
Other Investing Activities -$6.480M $33.27M $2.400M
YoY Change -120.76% 1286.25% -92.81%
Cash From Investing Activities -$8.690M $32.49M $920.0K
YoY Change -128.1% 3431.52% -96.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 67.32M -690.0K -80.00K
YoY Change -41.37% 762.5% -108.89%
NET CHANGE
Cash From Operating Activities -62.31M -55.69M -31.95M
Cash From Investing Activities -8.690M 32.49M 920.0K
Cash From Financing Activities 67.32M -690.0K -80.00K
Net Change In Cash -3.680M -23.89M -31.11M
YoY Change -103.28% -23.21% -631.79%
FREE CASH FLOW
Cash From Operating Activities -$62.31M -$55.69M -$31.95M
Capital Expenditures -$2.210M -$780.0K -$1.480M
Free Cash Flow -$60.10M -$54.91M -$30.47M
YoY Change 80.92% 80.21% 36.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001479290
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36297
dei Entity Registrant Name
EntityRegistrantName
Revance Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0551645
dei Entity Address Address Line1
EntityAddressAddressLine1
7555 Gateway Boulevard
dei Entity Address City Or Town
EntityAddressCityOrTown
Newark
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94560
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
742-3400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RVNC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66549174 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
339439000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
171160000 USD
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
96392000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
118955000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2585000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
3976000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
0 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7713000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6487000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
450105000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
296602000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14843000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14755000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
144505000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
0 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
74849000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25446000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26531000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1245000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
730000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1154000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1669000 USD
CY2020Q3 us-gaap Assets
Assets
712147000 USD
CY2019Q4 us-gaap Assets
Assets
340287000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7860000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8010000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37659000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18636000 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10931000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7911000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4040000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3470000 USD
CY2020Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3163000 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2952000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
63653000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40979000 USD
CY2020Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
177377000 USD
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
74811000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
47948000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23453000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25870000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
339294000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
114797000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66587713 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66587713 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52374735 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52374735 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
67000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1420770000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1069639000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
372853000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
225490000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
712147000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1047984000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-844204000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
340287000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3835000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4192000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
324000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29130000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25847000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96027000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75368000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48183000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16739000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
99013000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
43245000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
2565000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
0 USD
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
3239000 USD
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
0 USD
CY2020Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
80963000 USD
CY2019Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
42586000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
199385000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
118613000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-77128000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-42540000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-195193000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-118289000 USD
CY2020Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
413000 USD
CY2019Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1329000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2868000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4495000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
4334000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
10738000 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q3 rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-62000 USD
CY2019Q3 rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-68000 USD
rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-211000 USD
rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-139000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-146000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-130000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-406000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-170000 USD
CY2020Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-81257000 USD
CY2019Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-41409000 USD
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-203680000 USD
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-114103000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-81257000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-41409000 USD
us-gaap Net Income Loss
NetIncomeLoss
-203780000 USD
us-gaap Net Income Loss
NetIncomeLoss
-114103000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-117000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81374000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41483000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-203783000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-114053000 USD
CY2020Q3 rvnc Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-81257000 USD
CY2019Q3 rvnc Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-41409000 USD
rvnc Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-203780000 USD
rvnc Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-114103000 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.34
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.67
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60526740 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43314831 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56233093 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42730983 shares
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 USD
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
108510000 USD
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66587713 shares
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
372853000 USD
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44108407 shares
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
151281000 USD
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66587713 shares
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
372853000 USD
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44108407 shares
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
151281000 USD
us-gaap Net Income Loss
NetIncomeLoss
-203780000 USD
us-gaap Net Income Loss
NetIncomeLoss
-114103000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
24574000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
12882000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
11184000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
7576000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5931000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2152000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1351000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2215000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-474000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-411000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2492000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-22000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3976000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1254000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1426000 USD
rvnc Increase Decreasein Operating Lease Rightof Use Assets
IncreaseDecreaseinOperatingLeaseRightofUseAssets
-1085000 USD
rvnc Increase Decreasein Operating Lease Rightof Use Assets
IncreaseDecreaseinOperatingLeaseRightofUseAssets
2414000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-515000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-999000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
147000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1050000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
17142000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3532000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
29883000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4676000 USD
rvnc Increase Decreasein Operating Lease Liabilities
IncreaseDecreaseinOperatingLeaseLiabilities
-1846000 USD
rvnc Increase Decreasein Operating Lease Liabilities
IncreaseDecreaseinOperatingLeaseLiabilities
1903000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-116188000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-72653000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
246500000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
183000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
16969000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
239821000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
228568000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1890000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2943000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
818000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
118000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20822000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48511000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
287500000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
rvnc Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount
ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount
15581000 USD
rvnc Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount
ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount
108100000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5476000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
480000 USD
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
28865000 USD
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9190000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6005000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1229000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
337000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
521000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
264160000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106830000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
168794000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14334000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171890000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73986000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
340684000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59652000 USD
us-gaap Stock Issued1
StockIssued1
188104000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
43400000 USD
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
336000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
313000 USD
rvnc Internally Developed Software Capitalized From Stock Based Compensation
InternallyDevelopedSoftwareCapitalizedFromStockBasedCompensation
415000 USD
rvnc Internally Developed Software Capitalized From Stock Based Compensation
InternallyDevelopedSoftwareCapitalizedFromStockBasedCompensation
0 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-81300000 USD
us-gaap Net Income Loss
NetIncomeLoss
-203800000 USD
CY2020Q3 rvnc Working Capital Surplus
WorkingCapitalSurplus
386500000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1050000000.00 USD
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
435800000 USD
rvnc Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum
CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum
P12M
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, the fair value of assets and liabilities assumed in business combinations, incremental borrowing rate used to measure operating lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, period of benefit associated with deferred costs, useful lives of customer contracts, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals including clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration in asset acquisitions, and income taxes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 has caused a global slowdown of economic activity which has decreased demand for a broad variety of goods and services, including from our potential customers, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic on, for instance, clinical trials and product launch timing. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.</span></div>
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3835000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4192000 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
31000000.0 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
31000000.0 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
425439000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
425439000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
282683000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
282686000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
425439000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
282686000 USD
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
CY2019 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
11200000 USD
CY2020Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
78534000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3685000 USD
CY2020Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
74849000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3000000.0 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3700000 USD
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3506000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
13983000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
13925000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
13925000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
8137000 USD
CY2020Q3 rvnc Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
5173000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
58649000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
4000000.0 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
18470000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7933000 USD
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8399000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4751000 USD
CY2020Q3 rvnc Accruals Clinical Trials Current
AccrualsClinicalTrialsCurrent
5046000 USD
CY2019Q4 rvnc Accruals Clinical Trials Current
AccrualsClinicalTrialsCurrent
4746000 USD
CY2020Q3 rvnc Accrued Inventory Current
AccruedInventoryCurrent
1725000 USD
CY2019Q4 rvnc Accrued Inventory Current
AccruedInventoryCurrent
0 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3019000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
4310000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
206000 USD
CY2020Q3 rvnc Accrued Nonrecurring Milestone Payment Current Portion
AccruedNonrecurringMilestonePaymentCurrentPortion
1000000 USD
CY2019Q4 rvnc Accrued Nonrecurring Milestone Payment Current Portion
AccruedNonrecurringMilestonePaymentCurrentPortion
1000000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37659000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18636000 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y2M12D
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P14Y
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1460000 USD
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1425000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
4193000 USD
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
282000 USD
CY2020Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1258000 USD
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
298000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
631000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
886000 USD
CY2020Q3 us-gaap Lease Cost
LeaseCost
1742000 USD
CY2019Q3 us-gaap Lease Cost
LeaseCost
1723000 USD
us-gaap Lease Cost
LeaseCost
4941000 USD
us-gaap Lease Cost
LeaseCost
5079000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1719000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7073000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5600000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5697000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5877000 USD
CY2020Q3 rvnc Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
12532000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
38498000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11005000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
27493000 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.119
CY2020Q3 rvnc Lessee Operating Lease Lease Not Yet Commenced Amount
LesseeOperatingLeaseLeaseNotYetCommencedAmount
6300000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
5071000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
4704000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
723000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3890000 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3159000 USD
CY2020Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2976000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7346000 USD
CY2020Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
96000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
230000 USD
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4330000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
10735000 USD
CY2020Q1 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
28900000 USD
CY2020Q1 rvnc Capped Calls Price Cap
CappedCallsPriceCap
48.88
CY2020Q1 rvnc Capped Calls Premium Percentage Over Sale Price
CappedCallsPremiumPercentageOverSalePrice
1
CY2020Q1 rvnc Capped Calls Number Of Shares Subject To Antidilution Adjustments
CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments
8900000 shares
CY2020Q1 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
28900000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10677000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4303000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24574000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12882000 USD
CY2020Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
305300000 USD
rvnc Indemnification Liability Recordedduring Period
IndemnificationLiabilityRecordedduringPeriod
0 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3835000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4192000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
324000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-77128000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-42540000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-195193000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-118289000 USD

Files In Submission

Name View Source Status
0001479290-20-000105-index-headers.html Edgar Link pending
0001479290-20-000105-index.html Edgar Link pending
0001479290-20-000105.txt Edgar Link pending
0001479290-20-000105-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvnc-20200930.htm Edgar Link pending
rvnc-20200930.xsd Edgar Link pending
rvnc-20200930_cal.xml Edgar Link unprocessable
rvnc-20200930_def.xml Edgar Link unprocessable
rvnc-20200930_htm.xml Edgar Link completed
rvnc-20200930_lab.xml Edgar Link unprocessable
rvnc-20200930_pre.xml Edgar Link unprocessable
rvncq32010-qexhibit102.htm Edgar Link pending
rvncq32010-qexhibit105.htm Edgar Link pending
rvncq32010-qexhibit311.htm Edgar Link pending
rvncq32010-qexhibit312.htm Edgar Link pending
rvncq32010-qexhibit321.htm Edgar Link pending
rvncq32010-qexhibit322.htm Edgar Link pending
rvncq320ex101areeagree.htm Edgar Link pending
Show.js Edgar Link pending